Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429910 · ClinicalTrials.gov registry record
Natural History Study of Patients With Chronic Myelogenous Leukemia
A clinical trial of Leukemia, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT00429910 is a study of Leukemia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 48 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00429910, a study of Leukemia, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Gathering information about patients with chronic myelogenous leukemia may help doctors learn more about the disease and find better methods of treatment and on-going care. PURPOSE: This natural history study is collecting health information and disease-related information over time from patients with newly diagnosed chronic myelogenous leukemia.
Conditions Studied
Study Locations (1)
Massachusetts
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429910
The ClinicalTrials.gov registry entry for NCT00429910 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (90% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 0 interventions.
NCT00429910 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00429910 about?
NCT00429910 is a clinical study titled "Natural History Study of Patients With Chronic Myelogenous Leukemia". RATIONALE: Gathering information about patients with chronic myelogenous leukemia may help doctors learn more about the disease and find better methods of treatment and on-going care. PURPOSE: This natural history study is collecting health information and disease-related information over time from...
What is the current status of trial NCT00429910?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2003-02. Estimated completion is 2005-09.
What conditions does trial NCT00429910 study?
This clinical trial studies the following conditions: Leukemia.
Who is sponsoring clinical trial NCT00429910?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00429910 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.